4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 5, 2009, Pages 1310-1313

  Mitchell, Lorna ^a   Wang, Zhi ^b   Hu, Lain Yen ^c   Kostlan, Catherine ^d   Carroll, Matthew ^c   Dettling, Danielle ^c   Du, Daniel ^c   Pocalyko, David ^c   Wade, Kimberly ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c PFIZER INC   (United States)

^d IDSC   (United States)

Author keywords

Androgen receptor; Androgen receptor antagonist; Antiandrogen; Sebum; Softdrug; Thioether; Topical

Indexed keywords

4 THIOBENZONITRILE DERIVATIVE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; BENZONATATE; UNCLASSIFIED DRUG; WAX;

ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; EAR; EXPERIMENTAL MODEL; GOLDEN SYRIAN HAMSTER; HAMSTER; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; SEBUM SECRETION;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE; CRICETINAE; HUMANS; INSECTS; MALE; MESOCRICETUS; NITRILES; PROTEIN BINDING; RECEPTORS, ANDROGEN; SEBUM;

MESOCRICETUS AURATUS;

EID: 60449087089     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.063     Document Type: Article

References (19)

1. Redmond G.P., and Bergfeld W.F. Cleveland Clinic J. Med. 57 (1990) 428
2. Bingham K.D., Low M., and Wyatt E.H. Lancet 314 (1979) 304
3. Gruber D.M., Sator M.O., Joura E.A., Kokoschka E.M., Heinza G., and Huber J.C. Arch. Dermatol. 134 (1998) 459
4. Gao W., Bohl C.E., and Dalton J.T. Chem. Rev. 105 (2005) 3352
5. Hu L.Y., Du D., Hoffman J., Smith Y., Fedij V., Kostlan C., Johnson T.R., Huang Y., Kesten S., Harter W., Yue W.S., Li J.J., Barvian N., Mitchell L.H., Lei H.J., Lefker B., Carroll M., Dettling D., Krieger-Burke T., Samas B., Yalamanchili R., Lapham K., Pocalyko D., Sliskovic D., Ciotti S., Stoller B., Hena M.A., Ding Q., Maiti S.N., Stier M., and Welgus H. Bioorg. Med. Chem. Lett. 17 (2007) 5983
6. Van Camp J.A., Hu L.-Y., Kostlan C., Lefker B., Li J.J., Mitchell L.H., Wang Z., Yue W.-S., Carroll M., Dettling D., Du D., Pocalyko D., and Wade K. Bioorg. Med. Chem. Lett. 17 (2007) 5529
7. Hu L.-Y., Lei H.J., Du D., Johnson T.R., Fedij V., Kostlan C., Yue W.-S., Lovdahl M., Li J.J., Carroll M., Dettling D., Asbill J., Fan C., Wade K., Pocalyko D., Lapham K., Yalamanchili R., Samas B., Vrieze D., Ciotti S., Krieger-Burke T., Sliskovic D., and Welgus H. Bioorg. Med. Chem. Lett. 17 (2007) 5693
8. Bodor N., and Buchwald P. Mol. Biotechnol. 26 (2004) 123
9. 50). Compound RU-58841 was run as a standard revealing an inter-run variability within 2-fold.
10. The androgen receptor cellular functional assay was conducted in a human breast tumor cell line expressing androgen receptor (MDA-MB453-MMTV clone 54-19). The cell line is a stably transfected cell line with MDA-MB453 cell background. A MMTV minimal promoter containing Androgen Response Element (ARE) was first cloned in front of a firefly luciferase receptor gene. Then the cascade was cloned into a transfection vector pUV120-puro. Electroporation was used for transfecting MDAMB-453 cells and a puromycin resistant stable cell line was selected. See Chang, C.; Wang, C.; DeLuca, H. F.; Ross, T. F.; Shih, C.C.-Y. Proc. Natl. Acad. Sci. USA. 1992, 89, 5946.
11. Collection of metabolic stability data failed using our high through-put procedure as these thioether compounds did not give mass ion under the standard conditions. Alternative studies were not conducted due to the moderate level of in vivo efficacy in this series.
12. Generalized procedures for the synthesis of diphenylthioethers from commercially available thiols; Method A: a mixture of 4-fluoro-2-trifluoromethyl-benzonitrile (or 4-fluoro-2-methoxy-benzonitrile), the thiol (1.05 equiv), and cesium carbonate (2 equiv) in dimethylformamide was stirred at room temperature or at 50-70 °C for 1 h-2 days or until reaction was complete. The reaction mixture was poured into ice and if the product precipitated out it was collected by filtration. Otherwise the reaction mixture was extracted twice with ethyl acetate, the combined extracts were dried with brine and then magnesium sulfate and concentrated on the rotovap. If necessary the crude product was purified by column chromatography on silica. Array method A: a mixture of 4-fluoro-2-trifluoromethyl-benzonitrile, the thiol (1 equiv), and cesium carbonate (1.5 equiv) in acetonitrile was heated at 60 °C overnight. The reaction mixture was then diluted with acetonitrile and an excess of silica supported maleimide was added. The reaction mixture was heated at 40 °C for 2 h and then filtered. The solvent was evaporated. The product purified by HPLC using an XTerra RP18, 30 × 100 mm column eluted with an acetonitrile, water, formic acid solution. Array method B: a mixture of 4-iodo-2-methoxy-benzonitrile, the thiol (1 equiv), and cesium carbonate (1.5 equiv) in dimethylformamide was heated at 65 °C for 2 days. The reaction mixture was then diluted with acetonitrile and an excess of silica supported maleimide was added. The reaction mixture was heated at 40 °C for 2 h and then filtered. The solvent was evaporated. The product was purified by HPLC using a Sunfire 19 × 100 mm Prep C18 OBD 5 micron column with an acetonitrile, water, formic acid solution.
13. Koch H. Drugs Today 20 (1984) 561
14. Fradet Y. Exp. Rev. Anticancer Ther. 4 (2004) 37
15. Lloyd-Jones G.C., Moseley J.D., and Renny J.S. Synthesis (2008) 661
16. 1H NMR (400 MHz, CHLOROFORM-d) δppm 3.69 (1 H, s), 3.92 (3 H, s), 6.86 (1 H, d), 6.82 (1 H, d), 7.39 (1 H, d).
17. Thiboutot D. J. Invest. Dermatol. 123 (2004) 1
18. Miller C.G., Wojnarowska F.T., Dowd P.M., Ashton R.E., O'Brien T.J., Griffiths W.A., and Jacobs H.S. Br. J. Dermatol. 114 (1986) 705
19. 2), sealed, and stored at -80 °C until for sample lipid extraction and HPLC lipid analysis. See Plewig, G.; Luderschmidt, C. J. invest. Dermatol. 1977, 68, 171.